logo
eClinicalWorks and healow Genie to Transform Patient Communication at Pulmonary and Sleep of Tampa Bay

eClinicalWorks and healow Genie to Transform Patient Communication at Pulmonary and Sleep of Tampa Bay

Business Wire13-05-2025

WESTBOROUGH, Mass.--(BUSINESS WIRE)-- eClinicalWorks®, the largest ambulatory cloud EHR, today announced that Pulmonary and Sleep of Tampa Bay has selected healow® Genie, a first-of-its-kind, EHR-agnostic, AI-powered contact center solution, for implementation across its practice. Using text, chatbot, and voice call options, the integration of healow Genie ensures patients can engage with their health information 24/7. The AI agent will handle responsibilities such as scheduling appointments, managing bill payments, and overseeing medication refills or referral requests, helping alleviate administrative burdens.
'We're excited to introduce healow Genie into our practice,' said Dr. Dragos Zanchi, Pulmonologist at Pulmonary and Sleep of Tampa Bay. 'healow Genie will help us screen all our calls, sometimes up to 500 phone calls a day, which is extremely important. Not all phone calls are equal. If we have a screening tool that helps us discern priority, that is really going to free up our staff to deal with emergency situations and enhance outreach, thus transforming our patient care service.'
Pulmonary & Sleep of Tampa Bay provides safe, cutting-edge, personalized diagnosis and treatment for pulmonary diseases, lung cancer, allergies, and sleep disorders. With a footprint in three strategic locations in Tampa, including Brandon, Wesley Chapel, and Tampa, they ensure the community's healthcare services are always within reach.
'We are thrilled to collaborate with Pulmonary & Sleep of Tampa Bay and aid them in maintaining their commitment to the highest standard of patient care," said Girish Navani, CEO and founder of eClinicalWorks. "Integrating the AI-powered contact center solution, healow Genie, will streamline operations and offer 24/7 support. From managing appointments to prescription handling, it will bring unprecedented efficiency. We're confident that this partnership will enhance patient engagement and satisfaction and significantly improve operational cost efficiency.'
healow Genie is the first of its kind, EHR-agnostic, AI contact center solution that offers patients real-time assistance via voice calls, texts, or chatbots. Its integration with eClinicalWorks EHR makes it a preferred AI-powered call center choice for specialty practices. The AI assistant reduces administrative burden and improves patient engagement. To learn more about the practice's story, hear from Dr. Dragos Zanchi in this video.
About Pulmonary & Sleep of Tampa Bay
Pulmonary & Sleep of Tampa Bay is a leading medical group accredited by the Joint Commission and dedicated to providing the highest level of patient care in the field of pulmonary diseases, lung cancer, allergies, and sleep disorders. With a relentless commitment to safety and quality, the practice is deeply rooted in continually improving patient care standards. It has three convenient locations across Tampa, Brandon, and Wesley Chapel and offers state-of-the-art, personalized diagnosis and treatment options. Its comprehensive services include medical equipment and supplies through CPAP Online Supplies, further enhancing its patient care capabilities. For more information, visit pulmonaryandsleephealth.com.
About eClinicalWorks
eClinicalWorks was founded in 1999 to help digitize paper charts for ambulatory practices. Today, eClinicalWorks leads the nation in innovation with cloud-based Electronic Health Records and Practice Management solutions. In addition, we help ambulatory practices, specialists, health centers, urgent care facilities, and hospital systems manage their revenue cycle, patient relationships, and Population Health initiatives. More than 180,000 providers and 1 million medical professionals rely upon the power and scalability of the eCW Cloud for flexible clinical documentation, better front-office workflows, and more efficient billing driven by Robotic Process Automation. We combine innovation, leading-edge technology, and a commitment to patient safety to enable practices to grow and thrive amid the challenges of 21st-century healthcare. For more information, visit www.eclinicalworks.com, follow us on LinkedIn, Facebook and X/Twitter, or call (866) 888-6929.
About healow Genie
healow Genie is a first-of-its-kind, EHR-agnostic, AI-powered contact center solution designed to enhance patient engagement by providing patients 24/7 access to vital health information via voice call, text, or chatbot. It offers a comprehensive suite of features, including patient self-service, intelligent assistant, automated after-hours service, and conversational smart campaigns. Genie improves patient satisfaction, reduces administrative burdens on staff, and lowers overall operational costs. For more information, visit https://genie.healow.com/.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Align Technology Connects With Over 2,000 Doctors and Practice Staff at the 2025 Invisalign ® Asia Pacific (APAC) Summit
Align Technology Connects With Over 2,000 Doctors and Practice Staff at the 2025 Invisalign ® Asia Pacific (APAC) Summit

Business Wire

time20 hours ago

  • Business Wire

Align Technology Connects With Over 2,000 Doctors and Practice Staff at the 2025 Invisalign ® Asia Pacific (APAC) Summit

BANGKOK--(BUSINESS WIRE)--Align Technology, Inc. ('Align') (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign ® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today shared highlights from the 2025 Invisalign ® Asia Pacific ('APAC') Summit held in Bangkok, Thailand, June 5 – 7, 2025. 'With more than 3 million Invisalign smiles across Asia Pacific, we know that this region sees some of the toughest clinical challenges in the field of dentistry,' said David Carr, Align executive vice president and managing director, APAC. 'The 2025 Invisalign Asia Pacific Summit underscores the importance of continued innovation and education. We are committed to working in partnership with doctors across the region in developing Invisalign treatment protocols that can help them transform smiles and change lives for even more patients.' Over three days, more than 2,000 doctors, practice team members, partners, and Align staff from across the region came together to explore the latest innovations in digital orthodontics and restorative dentistry. The summit featured over 60 expert speakers and more than 50 immersive breakout lectures and hands-on workshops, all designed to help doctors elevate clinical outcomes, streamline workflows, and grow their practices. Key topics covered include kids and teen, complex treatments, comprehensive dentistry and practice growth. 'This meeting provided us with a platform to connect with doctors across the full Asia Pacific region, encourage ongoing learning and sharing and showcase how our global innovations can support doctors in this market,' said Gigi Tsui, Align senior director, clinical, APAC. 'As we celebrate 20 million Invisalign smiles globally, including 3 million Invisalign smiles across the Asia Pacific region, it's critical that we continue to engage doctors for feedback and insights. This is fundamental to developing new innovations that meet the unique needs of doctors and patients across this region.' Attendees explored new developments across multiple interactive zones in the Innovation Hub, including: Kids and Teens: Featuring Invisalign First™, Invisalign® Palatal Expander System, and Invisalign® System with mandibular advancement featuring occlusal blocks ('MAOB'). ClinCheck® signature experience: Highlighting the 1-page Rx form (Flex Rx), preference templates, and ClinCheck ® Live Update. Comprehensive Dentistry: Showcasing iTero Lumina™ Pro dental imaging system, iTero™ intraoral scanner, Invisalign Smile Architect™, and Invisalign® Smile Video. Consumer & Branding: Demonstrating branding and tools to help doctors raise awareness of digital treatment options among patients of all ages. Clinical Excellence: Sharing clinical tools, evidence-based resources, education and insights available to doctors and staff. The summit also featured a Women Leadership session and provider recognition and lifetime achievement awardees. In addition to the core Asia Pacific Invisalign Summit, over 300 delegates across 78 universities also attended the Align APAC University Forum hosted at the renowned Chulalongkorn University in Bangkok. The forum served as a dynamic platform for cross-border collaboration and meaningful dialogue on how Align's evidence-based approach and cutting-edge innovations complements academic excellence and clinical training. Key highlights included keynote presentations by industry experts, interactive case-based discussions, resident showcases, and panels on integrating aligner therapy into university curriculum. The event also celebrated academic excellence with the APAC Case Challenge and Align research awards for APAC, while fostering peer-to-peer collaboration and inspiring the next generation of orthodontic leaders. About Align Technology, Inc. Align Technology designs and manufactures the Invisalign ® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 281.4 thousand doctor customers and are key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 28 years, Align has helped doctors treat over 20.1 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit for more information. For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit For additional information about the iTero digital scanning system, please visit For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.

Chemed To Report Second-Quarter 2025 Earnings July 29, 2025
Chemed To Report Second-Quarter 2025 Earnings July 29, 2025

Business Wire

time20 hours ago

  • Business Wire

Chemed To Report Second-Quarter 2025 Earnings July 29, 2025

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the second quarter ended June 30, 2025, on Tuesday, July 29, 2025, following the close of trading on the New York Stock Exchange. Chemed also announced developments related to second quarter earnings and full year 2025 guidance. In prior public statements, management discussed the possibility that the VITAS subsidiary could have an aggregate Medicare Cap billing limitation (Medicare Cap) related to its Florida consolidated program, excluding Tallahassee. However, as of the most recent quarterly earnings update, VITAS internal projections showed that the Florida consolidated program would end the 2025 government fiscal year ending on September 30, 2025 (2025 Cap Year) with a Medicare Cap cushion. Actual Medicare admissions in both April and May 2025 in Florida were weaker than anticipated and lower than VITAS' internal projections. As a result, VITAS now projects a Medicare Cap revenue limitation for the 2025 Cap Year of $18 million to $25 million related to the Florida consolidated program, excluding Tallahassee. The above projection includes actual results through May. Actual June results, which show better admissions than projected through the first half of the month, and actual results in the third quarter could have a significant impact on this projection. Previous guidance for 2025 earnings did not include any Florida Medicare Cap. The source of the Medicare Cap in the Florida consolidated program relates to two factors. The first factor is the 'community access' program. While community access has provided for a higher-than-average ADC growth rate and revenue growth rate at VITAS over the past two years, it adds pressure to the Medicare Cap due to patients accessing hospice care earlier in their disease trajectory. The second factor is the rate differential between the nationally determined increase in the Medicare Cap per admission and the actual reimbursement increase in our Florida consolidated programs, excluding Tallahassee, for the 2025 Cap Year. Specifically, the Medicare Cap per admission amount increased 2.9% while the Florida consolidated program reimbursement increase was 5.2%. VITAS estimates this rate differential will negatively impact the Florida consolidated program's Medicare Cap calculation by approximately $25 million for the 2025 government fiscal year, accounting for most, if not all, of the total revenue limitation discussed above. On June 20, 2025, the State of Florida announced that VITAS has received a Certificate of Need (CON) to begin operating in Pinellas County, Florida. Pinellas is the most densely populated county in Florida and has a hospice utilization rate below the state average. There were approximately 8,600 Medicare admissions to existing hospice providers in Pinellas County in 2024. Entering Pinellas County represents a significant opportunity for VITAS in 2026 and beyond for both overall growth and Medicare Cap mitigation. Based on the new start locations in Florida, primarily Marion County and Pinellas County, combined with operational changes currently being made in the Florida programs, management expects not to have any significant level of Medicare Cap revenue limitation in our Florida consolidated program for the 2026 fiscal year. This expectation assumes that the rate differential discussed above does not recur for the 2026 Cap Year. In the event that the rate differential does recur, VITAS will respond with further mitigation strategies at the outset of the 2026 Cap Year. While less financially significant than the VITAS Medicare Cap situation, during the second quarter of 2025, Roto-Rooter began to experience unexpected weakness in its residential business' demand compared to internal projections. This weakness represents a break from the trends experienced in the first quarter of 2025. Preliminary results for commercial demand in the second quarter of 2025 continue to reflect improved trends but not enough to offset the lower residential demand. Management is in the process of analyzing second quarter performance and the impact of these developments on second quarter results and on full-year 2025 guidance. A full discussion of the analysis will be included with our second quarter 2025 release and related investor conference call. Chemed will host a conference call and webcast at 10 a.m., ET, on Wednesday, July 30, 2025, to discuss the company's quarterly results and to provide an update on its business. Participants may access a live webcast of the conference call through the investor relations section of Chemed's website, Investor Relations Home | Chemed Corporation or the hosting website Participants may also register via teleconference at: Once registration is completed, participants will be provided with a dial-in number containing a personalized conference code to access the call. All participants are instructed to dial-in 15 minutes prior to the start time. A taped replay of the conference call will be available beginning approximately two hours after the call's conclusion. You may access the replay via webcast through the investor relations section of Chemed's website. Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation ( operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of end-of-life hospice care and Roto-Rooter is the nation's leading provider of plumbing and drain cleaning services. SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 REGARDING FORWARD-LOOKING INFORMATION Statements in this press release contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as 'anticipate,' 'intend,' 'plan,' 'goal,' 'seek,' 'believe,' 'project,' 'estimate,' 'expect,' 'strategy,' 'future,' 'likely,' 'may,' 'should,' 'will' and similar references to future periods and are based upon assumptions subject to certain known and unknown risks, uncertainties, contingencies and other factors, including, but not limited to, the impact of laws and regulations on Chemed's operations, including Medicare Cap and Medicare reimbursement rates, Chemed's estimates of the effect of Medicare Cap on VITAS' revenues and future prospects, Chemed's expectations regarding VITAS' patient mix, VITAS's future prospects in Pinellas County, FL and Chemed's expectations regarding demand for Roter-Rooter's services. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Chemed's control. Chemed's actual results and financial condition may differ materially from those indicated in the forward-looking statements included in this press release, including as a result of the risks described above and those described in the Chemed's Annual Report on Form 10-K for the year ended December 31, 2024 and in its Quarterly Reports filed in 2025. Any forward-looking statement made by Chemed in this press release are based only on information currently available to Chemed and speaks only as of the date on which it is made. Chemed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

PRD Therapeutics宣布啟動PRD001的首例人體研究
PRD Therapeutics宣布啟動PRD001的首例人體研究

Business Wire

timea day ago

  • Business Wire

PRD Therapeutics宣布啟動PRD001的首例人體研究

東京--(BUSINESS WIRE)--(美國商業資訊)-- PRD Therapeutics, Inc.是一家臨床階段公司,專注于開發靶向純合子家族性高膽固醇血症(HoFH)和代謝功能障礙相關脂肪性肝病(MASH/MASLD)的新型脂質代謝調節劑。該公司今日宣布,近期已啟動PRD001的首例人體(FIH)臨床試驗給藥。PRD001是一款同類首創的SOAT2(原稱ACAT2)選擇性抑制劑。 PRD Therapeutics執行長兼共同創辦人Kanji Hosoda博士表示:「我們很高興啟動PRD001臨床試驗的給藥。此前已展開過多項針對SOAT1/2雙重抑制劑或SOAT1選擇性抑制劑的臨床試驗,但這是第一個針對SOAT2選擇性抑制劑的臨床試驗。多項關於SOAT1或2基因敲除小鼠的研究結果已發表,顯示僅敲除或抑制SOAT2對證明安全性和有效性至關重要。PRD001是全球第一個且唯一的SOAT2選擇性抑制劑,可望也在人體中展現安全性和有效性。我們的臨床前動物模型(LDL-R KO小鼠;HoFH模型,以及高脂飲食誘導的MASH模型小鼠)顯示,PRD001可降低血液和肝臟脂質水準,抑制脂肪肝和動脈粥樣硬化的進展,且無不良事件。對於LDL受體活性缺失或極低的HoFH病患,PRD001可望成為同類第一個有效且安全的口服療法。」 該FIH 1期研究旨在評估PRD001在成年健康志願者中的安全性、耐受性、藥物動力學及早期療效跡象(LDL-C降低效應,以及使用MRI-PDFF檢測的肝臟脂肪量化值)。更多資訊可在 NCT07034183 查詢。 關於PRD001 PRD001是同類首創的口服小分子SOAT2選擇性抑制劑。它透過單一藥物獨特控制脂質代謝的三大關鍵途徑:肝臟膽固醇合成、小腸膽固醇吸收以及血液LDL-C攝取,從而強效降低血液LDL-C水準,且不依賴LDL受體。 本研發專案由日本醫療研究開發機構(AMED)透過 製藥初創企業生態系統強化計畫 提供支援(專案名稱:「同類首創口服脂質代謝調節劑PRD001的開發及脂質代謝紊亂的POC驗證」)。 免責聲明:本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用,煩請參照原文,原文版本乃唯一具法律效力之版本。

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store